Table 2.

Efficacy and safety end points of pivotal phase III clinical trials evaluating risankizumab, tildrakizumab, and guselkumab.

	Risankizumab [UltIMMa-1]	Risankizumab [UltIMMa-2]	Tildrakizumab 100 mg [reSURFACE 1]b	Tildrakizumab 100 mg [reSURFACE2]b	Guselkumab [VOYAGE 1]	Guselkumab [VOYAGE 2]
Number of patients receiving the study drug	304	294	309	307	334	496
PASI-90 at Week 16	229 [75·3%]	220 [74·8%]	107 [35%]a	119 [39%]a	241 [73.3]	347 [70.0]
sPGA 0 or 1 at Week 16	267 [87·8%]	246 [83·7%]	179 [58%]a	168 [55%]a	280 [85.1]	417 [84.1]
PASI-100 at Week 16	109 [35·9%]	149 [50·7%]	43 [14%]a	38 [12%]a	123 [37.4]	169 [34.1]
PASI-90 at Week 52	249 [81·9%]	237 [80·6%]	N/A	N/A	251 [76.3]c	N/Ad
PASI-100 at Week 52	171 [56·3%]	175 [59·5%]	N/A	N/A	156 [47.4]c	N/Ad
sPGA 0 at Week 52	175 [57·6%]	175 [59·5%]	N/A	N/A	166 [50.5]c	N/Ad
Severe adverse events	6 [2·0%]	7 [2·4%]	5 [2%]	4 [1%]	8 [2.4]	2 [1.0]
Adjudicated major adverse cardiovascular event	0	0	1 [<1%]	0	1 [0.3]	0
Serious infections	1 [0·3%]	3 [1·0%]	1 [<1%]	0	0	1 [0.5]

N/A, not available.

^aThe primary efficacy endpoint in both resurface 1 and 2 was PASI response at Week 12.

^breSURFACE trials design does not allow to evaluate PASI and PGA responses after Week 24.

^cVOYAGE 1 evaluated PASI and PGA responses up to Week 48.

^dVOYAGE 2 design does not allow to evaluate PASI and PGA responses after Week 24.